๐ผPandailyโขStalecollected in 9m
Airdoc Marks 10 Years of Global AI Health Expansion
๐กSee how a specialized AI diagnostic tool scaled to 30 million users across 50+ countries.
โก 30-Second TL;DR
What Changed
10-year milestone since founding in Beijing's Haidian Science and Technology Park
Why It Matters
Airdoc's scale demonstrates the viability of AI-driven diagnostic tools in public health. It highlights the potential for specialized medical AI to achieve massive global adoption.
What To Do Next
Analyze Airdoc's regulatory compliance strategy for medical AI deployment across diverse international markets.
Who should care:Founders & Product Leaders
Key Points
- โข10-year milestone since founding in Beijing's Haidian Science and Technology Park
- โขReached 30 million AI-powered retinal screenings globally
- โขExpanded operations to over 50 countries worldwide
๐ง Deep Insight
Web-grounded analysis with 14 cited sources.
๐ Enhanced Key Takeaways
- โขAirdoc was founded in 2015 by Ray Zhang (also known as Zhang Dalei) in Beijing, specializing in AI software for assessing chronic disease risks based on fundus images.
- โขThe company's AI-powered retinal imaging tool can detect 35 eye conditions, including diabetic retinopathy, and 9 chronic disease risks, such as arteriosclerosis and glucose metabolism issues, with reports generated in approximately 3 minutes.
- โขAirdoc's core product, Airdoc-AIFUNDUS Version 2.0, received a Class III medical device registration certificate from China's National Medical Products Administration (NMPA) in April 2025, enabling full-scale market launch for its fundus camera products.
- โขAirdoc became a publicly listed company on November 5, 2021.
- โขAirdoc has developed its own AI system, the Wanyu Medical Large Model, which it is expanding beyond image-based diagnosis to include general medical Q&A and health management.
๐ Competitor Analysisโธ Show
| Company | Focus/Capabilities |
|---|---|
| Airdoc | AI-powered retinal imaging for 35 eye conditions and 9 chronic disease risks (e.g., diabetic retinopathy, arteriosclerosis, glucose metabolism). Report generation in ~3 minutes. Portable camera AI-FD16aF. Reported up to 95% alignment with ophthalmologists' assessments. |
| Eyenuk, Inc. | AI-based screening for diabetic retinopathy. Algorithms tested in real-world settings. |
| Digital Diagnostics Inc. | Leading player in autonomous AI-powered ophthalmology screening. |
| Retina-AI Health | AI-based screening for diabetic retinopathy. Algorithms tested in real-world settings. |
| Retmarker | AI-based screening for diabetic retinopathy. Algorithms tested in real-world settings. |
| OphtAI | AI-based software for automated screening and grading of retinal diseases for population screening programs. Algorithms tested in real-world settings. |
๐ ๏ธ Technical Deep Dive
- Airdoc's system utilizes a fully-automatic fundus camera to capture retinal images, which are then transmitted to an AI module for analysis.
- The AI performs quantitative analysis of lesions and physiological structures, as well as assessing the risk of chronic diseases, allowing for continuous comparison with a patient's medical history.
- The system is capable of detecting 35 distinct eye conditions and 9 chronic disease risks.
- The AI algorithms are designed to achieve diagnostic accuracy reportedly up to 95% alignment with ophthalmologists' assessments.
- Image analysis by the AI system is remarkably fast, taking approximately 20 to 30 milliseconds per image.
- Airdoc has developed its proprietary AI system, the Wanyu Medical Large Model, which is being expanded to cover broader health management and general medical Q&A beyond just image-based diagnosis.
- The portable digital retinal camera, model AI-FD16aF, weighs 1.5 kg, measures 280 ร 240 ร 130 mm (LxWxH), features voice commands, and offers a 40-degree field of view, capturing images in under a minute.
๐ฎ Future ImplicationsAI analysis grounded in cited sources
Airdoc will likely expand its AI capabilities beyond retinal image analysis to broader health management and general medical Q&A.
The company has already unveiled its Wanyu Medical Large Model and is actively trying to extend its reach from image-based diagnosis to general medical Q&A and health management.
Airdoc's recent Class III medical device approval in China will significantly accelerate its commercialization and market penetration within the country.
This regulatory approval in April 2025 unlocks large revenue streams from medical institutions and health screening programs in China.
Airdoc will continue to face intense competition in the autonomous AI ophthalmology screening market, necessitating continuous innovation in accuracy and disease detection.
The market has numerous players, and studies indicate varying performance levels among AI algorithms, suggesting a need for ongoing improvement to maintain a competitive edge.
โณ Timeline
2015
Airdoc founded by Ray Zhang in Beijing.
2018-04
First funding round (Series B).
2021-06
Series D funding round.
2021-11-05
Airdoc got listed (IPO).
2025-04
Airdoc-AIFUNDUS Version 2.0 received Class III medical device registration certificate from NMPA.
2025-07
Airdoc unveiled its Wanyu Medical Large Model.
๐ Sources (14)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
๐ฐ
Weekly AI Recap
Read this week's curated digest of top AI events โ
๐Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: Pandaily โ